These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25341152)

  • 1. FDG PET/CT in the management of colorectal and anal cancers.
    Agarwal A; Marcus C; Xiao J; Nene P; Kachnic LA; Subramaniam RM
    AJR Am J Roentgenol; 2014 Nov; 203(5):1109-19. PubMed ID: 25341152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of retrospective image fusion of ¹⁸F-FDG PET and MRI for preoperative staging of head and neck cancer: comparison with PET/CT and contrast-enhanced neck MRI.
    Kanda T; Kitajima K; Suenaga Y; Konishi J; Sasaki R; Morimoto K; Saito M; Otsuki N; Nibu K; Sugimura K
    Eur J Radiol; 2013 Nov; 82(11):2005-10. PubMed ID: 23891295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response assessment of colorectal liver metastases with contrast enhanced CT/18F-FDG PET.
    García Vicente AM; Domínguez Ferreras E; Sánchez Pérez V; Poblete García VM; Villa Guzmán JC; Jiménez Aragón F; Pineda Pineda MD; Molino Trinidad C; Soriano Castrejón Á
    Eur J Radiol; 2013 Jun; 82(6):e255-61. PubMed ID: 23414715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of fusion of PET and MRI for staging of endometrial cancer: comparison with ¹⁸F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI.
    Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Takahashi S; Ebina Y; Miyahara Y; Yamada H; Sugimura K
    Eur J Radiol; 2013 Oct; 82(10):1672-6. PubMed ID: 23727380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing central compartment neck dissection for squamous cell carcinoma of the larynx, hypopharynx, and esophagus.
    Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2013 May; 49(5):449-53. PubMed ID: 23321549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: comparison with PET and enhanced CT.
    Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
    Eur J Radiol; 2010 Feb; 73(2):324-8. PubMed ID: 19200683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
    Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
    Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
    Klumpp B; Schwenzer NF; Gatidis S; Koenigsrainer I; Koenigsrainer A; Beckert S; Mueller M; Claussen CD; Pfannenberg C
    Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
    Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
    J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review.
    Treglia G; Annunziata S; Sobic-Saranovic D; Bertagna F; Caldarella C; Giovanella L
    Acad Radiol; 2014 May; 21(5):675-84. PubMed ID: 24703482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pivotal role of FDG-PET/CT in modern medicine.
    Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
    Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET/CT of primary bone tumors.
    Costelloe CM; Chuang HH; Madewell JE
    AJR Am J Roentgenol; 2014 Jun; 202(6):W521-31. PubMed ID: 24848845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invited editorial: Response to therapy assessment of colorectal liver metastasis.
    Maffione AM; Rampin L; Blickman JG; Rubello D
    Eur J Radiol; 2013 Jun; 82(6):903-4. PubMed ID: 23518147
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
    Laurens ST; Oyen WJ
    PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
    Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.